Next Article in Journal
In Vitro Studies of Lipopolysaccharide-Mediated DNA Release of Podovirus HK620
Next Article in Special Issue
Phage Therapy Faces Evolutionary Challenges
Previous Article in Journal
Histone Modulation Blocks Treg-Induced Foxp3 Binding to the IL-2 Promoter of Virus-Specific CD8+ T Cells from Feline Immunodeficiency Virus-Infected Cats
Previous Article in Special Issue
Framing the Future with Bacteriophages in Agriculture
 
 
Review

Phage Therapy: What Have We Learned?

1
Bacteriophage Laboratory, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla Street 12, 53-114 Wroclaw, Poland
2
Phage Therapy Unit, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla Street 12, 53-114 Wroclaw, Poland
3
Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Nowogrodzka Street 59, 02-006 Warsaw, Poland
4
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego Street 5 A, 02-106 Warsaw, Poland
5
Autonomous Department of Microbial Biology, Faculty of Agriculture and Biology, Warsaw University of Life Sciences, Nowoursynowska Street 159, 02-776 Warsaw, Poland
6
Medical Sciences Institute, Katowice School of Economics, Harcerzy Września Street 3, 40-659 Katowice, Poland
7
Research and Development Center, Regional Specialized Hospital, Kamieńskiego 73a, 51-124 Wrocław, Poland
8
National Institute of Public Health NIZP, Chocimska Street 24, 00-971 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Current Address: Department of Medical Microbiology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Viruses 2018, 10(6), 288; https://doi.org/10.3390/v10060288
Received: 18 April 2018 / Revised: 11 May 2018 / Accepted: 22 May 2018 / Published: 28 May 2018
(This article belongs to the Special Issue Hurdles for Phage Therapy (PT) to Become a Reality)
In this article we explain how current events in the field of phage therapy may positively influence its future development. We discuss the shift in position of the authorities, academia, media, non-governmental organizations, regulatory agencies, patients, and doctors which could enable further advances in the research and application of the therapy. In addition, we discuss methods to obtain optimal phage preparations and suggest the potential of novel applications of phage therapy extending beyond its anti-bacterial action. View Full-Text
Keywords: phage therapy; experimental therapy; phage cocktails; anti-phage antibodies; prophage; immunomodulation phage therapy; experimental therapy; phage cocktails; anti-phage antibodies; prophage; immunomodulation
Show Figures

Graphical abstract

MDPI and ACS Style

Górski, A.; Międzybrodzki, R.; Łobocka, M.; Głowacka-Rutkowska, A.; Bednarek, A.; Borysowski, J.; Jończyk-Matysiak, E.; Łusiak-Szelachowska, M.; Weber-Dąbrowska, B.; Bagińska, N.; Letkiewicz, S.; Dąbrowska, K.; Scheres, J. Phage Therapy: What Have We Learned? Viruses 2018, 10, 288. https://doi.org/10.3390/v10060288

AMA Style

Górski A, Międzybrodzki R, Łobocka M, Głowacka-Rutkowska A, Bednarek A, Borysowski J, Jończyk-Matysiak E, Łusiak-Szelachowska M, Weber-Dąbrowska B, Bagińska N, Letkiewicz S, Dąbrowska K, Scheres J. Phage Therapy: What Have We Learned? Viruses. 2018; 10(6):288. https://doi.org/10.3390/v10060288

Chicago/Turabian Style

Górski, Andrzej, Ryszard Międzybrodzki, Małgorzata Łobocka, Aleksandra Głowacka-Rutkowska, Agnieszka Bednarek, Jan Borysowski, Ewa Jończyk-Matysiak, Marzanna Łusiak-Szelachowska, Beata Weber-Dąbrowska, Natalia Bagińska, Sławomir Letkiewicz, Krystyna Dąbrowska, and Jacques Scheres. 2018. "Phage Therapy: What Have We Learned?" Viruses 10, no. 6: 288. https://doi.org/10.3390/v10060288

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop